{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:12:39Z","timestamp":1786119159083,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Alveolar rhabdomyosarcoma (ARMS) is an aggressive subtype of rhabdomyosarcoma with generally poorer outcomes than embryonal rhabdomyosarcoma. We analyzed a large contemporary cohort to characterize survival outcomes and prognostic factors for ARMS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We identified patients with histologically confirmed ARMS from the Surveillance, Epidemiology, and End Results (SEER) database. Demographics, tumor characteristics (stage, primary site), and treatments (surgery, radiation, and chemotherapy) were extracted. Cancer-specific survival (CSS) was estimated with Kaplan\u2013Meier methods and compared using log-rank tests. Cox proportional hazards models were used for univariate and multivariate analysis of prognostic factors, with results reported as hazard ratios (HR) and 95% confidence intervals (CI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 592 ARMS patients were included [median age 14 years (interquartile range 7\u201325); 52% male; 73% White]. Primary tumors most commonly arose in extremities or trunk (64%), followed by head and neck sites (26%) and genitourinary locations (5%). Most patients received multimodal therapy: 44% underwent surgical resection, 70% received radiotherapy, and 92% received chemotherapy. The 5-year CSS for the entire cohort was approximately 43%. Distant metastasis was the strongest independent adverse prognostic factor (aHR: 2.9, 95% CI 2.13\u20133.92,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), and regional nodal involvement also independently worsened CSS (aHR: 1.46, 95% CI 1.07\u20131.99,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.016) compared to localized disease. Older age (\u226520) at diagnosis was associated with higher mortality risk (aHR: 1.82 vs. age &lt;10,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Notably, the use of surgery (aHR: 0.74,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.031) and radiation therapy (aHR: 0.62,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) were independently associated with improved CSS after controlling for stage and age.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this large population-based study, ARMS survival remains poor, especially for patients with metastatic disease or in older age groups. Distant metastases and age \u226520 were associated with markedly inferior outcomes, while local therapy with surgery and radiation conferred significant survival benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000004046","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:00:41Z","timestamp":1760342441000},"page":"81-87","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of survival in alveolar rhabdomyosarcoma in the US"],"prefix":"10.1097","volume":"88","author":[{"given":"Akef","family":"Obeidat","sequence":"first","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6292-7683","authenticated-orcid":false,"given":"Tarek Ziad","family":"Arabi","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliaa","family":"Amr","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mushtaq","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Hady","family":"Albitar","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nida","family":"Mariyam","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameeha","family":"Abdulwali","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Alaswad","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belal","family":"Sabbah","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"R1-20260514","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0051-2","article-title":"Rhabdomyosarcoma","volume":"5","author":"Skapek","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20260514","doi-asserted-by":"crossref","first-page":"367\u201386","DOI":"10.1016\/j.ejca.2022.05.036","article-title":"Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: a consensus view from European paediatric soft tissue sarcoma study group, children\u2019s oncology group and cooperative weichteilsarkom-studiengruppe","volume":"172","author":"Hettmer","year":"2022","journal-title":"Euro J Cancer"},{"key":"R3-20260514","doi-asserted-by":"crossref","first-page":"4218\u201326","DOI":"10.1002\/cncr.24465","article-title":"Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005","volume":"115","author":"Ognjanovic","year":"2009","journal-title":"Cancer"},{"key":"R4-20260514","doi-asserted-by":"crossref","first-page":"20363613241271669","DOI":"10.1177\/20363613241271669","article-title":"Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma patients on first-line systemic therapies: a single-institution cohort","volume":"16","author":"Nakazawa","year":"2024","journal-title":"Rare Tumors"},{"key":"R5-20260514","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.clon.2019.07.007","article-title":"Embryonal and alveolar rhabdomyosarcoma in adults: real-life data from a tertiary sarcoma centre","volume":"32","author":"Drabbe","year":"2020","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R6-20260514","doi-asserted-by":"crossref","first-page":"2226\u201330","DOI":"10.1002\/jor.24387","article-title":"Epidemiology, incidence, and survival of rhabdomyosarcoma subtypes: SEER and ICES database analysis","volume":"37","author":"Amer","year":"2019","journal-title":"J Orthop Res"},{"key":"R7-20260514","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3390\/cancers12071758","article-title":"Recent advances and challenges in the treatment of rhabdomyosarcoma","volume":"12","author":"Miwa","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R8-20260514","doi-asserted-by":"crossref","first-page":"3468\u201375","DOI":"10.1200\/JCO.1999.17.11.3468","article-title":"Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: a report from the intergroup rhabdomyosarcoma studies I to III","volume":"17","author":"Wolden","year":"1999","journal-title":"J Clin Oncol"},{"key":"R9-20260514","doi-asserted-by":"crossref","first-page":"e28832","DOI":"10.1002\/pbc.28832","article-title":"Alveolar rhabdomyosarcoma with regional nodal involvement: results of a combined analysis from two cooperative groups","volume":"68","author":"Gallego","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"R10-20260514","doi-asserted-by":"crossref","first-page":"738771","DOI":"10.3389\/fsurg.2021.738771","article-title":"Population-based survival analysis of patients with limb rhabdomyosarcoma and metastasis at diagnosis","volume":"8","author":"Yang","year":"2021","journal-title":"Front Surg"},{"key":"R11-20260514","article-title":"Revised Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery (STROCSS) Guideline: an update for the age of Artificial Intelligence","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R12-20260514","doi-asserted-by":"crossref","first-page":"610\u201330","DOI":"10.1200\/JCO.1995.13.3.610","article-title":"The third intergroup rhabdomyosarcoma study","volume":"13","author":"Crist","year":"1995","journal-title":"J Clin Oncol"},{"key":"R13-20260514","doi-asserted-by":"crossref","first-page":"3091\u2013102","DOI":"10.1200\/JCO.2001.19.12.3091","article-title":"Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease","volume":"19","author":"Crist","year":"2001","journal-title":"J Clin Oncol"},{"key":"R14-20260514","doi-asserted-by":"crossref","first-page":"e70215","DOI":"10.1002\/cam4.70215","article-title":"Prognostic factors in patients with localized and metastatic alveolar rhabdomyosarcoma. A report from two studies and two registries of the Cooperative Weichteilsarkom Studiengruppe CWS","volume":"14","author":"Koscielniak","year":"2025","journal-title":"Cancer Med"},{"key":"R15-20260514","doi-asserted-by":"crossref","first-page":"117\u201322","DOI":"10.1200\/JCO.2015.63.4048","article-title":"Intensive multiagent therapy, including dose-compressed cycles of ifosfamide\/etoposide and vincristine\/doxorubicin\/cyclophosphamide, irinotecan, and radiation, in patients with high-risk rhabdomyosarcoma: a report from the children\u2019s oncology group","volume":"34","author":"Weigel","year":"2016","journal-title":"J Clin Oncol"},{"key":"R16-20260514","doi-asserted-by":"crossref","first-page":"1371\u201378","DOI":"10.1177\/00099228231220236","article-title":"Prognostic factors in pediatric alveolar rhabdomyosarcoma: SEER analysis of 277 cases","volume":"63","author":"Zhang","year":"2024","journal-title":"Clin Pediatr (Phila)"},{"key":"R17-20260514","doi-asserted-by":"crossref","first-page":"2384\u201389","DOI":"10.1200\/JCO.2007.14.7207","article-title":"Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups","volume":"26","author":"Oberlin","year":"2008","journal-title":"J Clin Oncol"},{"key":"R18-20260514","doi-asserted-by":"crossref","first-page":"1932\u201344","DOI":"10.1038\/bjc.2014.497","article-title":"A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours","volume":"111","author":"Brana","year":"2014","journal-title":"Br J Cancer"},{"key":"R19-20260514","doi-asserted-by":"crossref","first-page":"878367","DOI":"10.3389\/fonc.2022.878367","article-title":"No improvement of survival for alveolar rhabdomyosarcoma patients after HLA-matched versus -mismatched allogeneic hematopoietic stem cell transplantation compared to standard-of-care therapy","volume":"12","author":"Schober","year":"2022","journal-title":"Front Oncol"},{"key":"R20-20260514","first-page":"94\u2013101","article-title":"Allogeneic hematopoietic stem cell transplantation for alveolar rhabdomyosarcoma: the first clinical experience of haploidentical transplantation","volume":"19","author":"Andreeva","year":"2020","journal-title":"Pediatric Hematol\/Oncol Immunopathol"},{"key":"R21-20260514","doi-asserted-by":"crossref","first-page":"e29511","DOI":"10.1002\/pbc.29511","article-title":"An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children\u2019s Oncology Group clinical trials","volume":"69","author":"Haduong","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"R22-20260514","first-page":"415\u201319","article-title":"Risk stratification of rhabdomyosarcoma: a moving target","author":"Arndt","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R23-20260514","doi-asserted-by":"crossref","first-page":"64\u201373","DOI":"10.1002\/pbc.10441","article-title":"Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft tissue sarcoma committee of the children\u2019s oncology group","volume":"42","author":"Joshi","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"R24-20260514","doi-asserted-by":"crossref","first-page":"3844\u201351","DOI":"10.1200\/JCO.2005.05.3801","article-title":"Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the children\u2019s oncology group","volume":"24","author":"Meza","year":"2006","journal-title":"J Clin Oncol"},{"key":"R25-20260514","doi-asserted-by":"crossref","first-page":"e30847","DOI":"10.1002\/pbc.30847","article-title":"Adolescents and young adults with rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children\u2019s oncology group","volume":"71","author":"Harrison","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"R26-20260514","doi-asserted-by":"crossref","first-page":"101055","DOI":"10.1016\/j.adro.2022.101055","article-title":"Adult head and neck rhabdomyosarcoma: management, outcomes, and the effect of intensity modulated radiation therapy on locoregional control","volume":"7","author":"Hahn","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"R27-20260514","doi-asserted-by":"crossref","first-page":"e26859","DOI":"10.1002\/pbc.26859","article-title":"Local therapy to distant metastatic sites in stage IV rhabdomyosarcoma","volume":"65","author":"Mohan","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R28-20260514","doi-asserted-by":"crossref","first-page":"e29853","DOI":"10.1002\/pbc.29853","article-title":"Metastatic rhabdomyosarcoma: evidence of the impact of radiotherapy on survival. A retrospective single-center experience","volume":"69","author":"Ferrari","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"R29-20260514","doi-asserted-by":"crossref","first-page":"193\u2013201","DOI":"10.1016\/j.ejca.2014.11.009","article-title":"Does aggressive local treatment have an impact on survival in children with metastatic rhabdomyosarcoma?","volume":"51","author":"Ben Arush","year":"2015","journal-title":"Eur J Cancer"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000004046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:41:25Z","timestamp":1786038085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000004046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000004046","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"2025-06-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}